Abstract 10P
Background
As a result of a significant decrease in smoking prevalence in many countries, the overall incidence of head and neck squamous cell carcinoma (HNSCC) is declining. However, there is a growing recognition of an increased incidence of oral tongue squamous cell carcinoma (OTSCC) in non-smokers and non-drinkers (NSND) for reasons that are yet to be fully understood. OTSCC in NSND and smoker-drinker (SD) individuals have different molecular profiles, as well as distinct immune microenvironments, which may affect their susceptibility to targeted therapies and immunotherapy. The prognostic value of tumor-infiltrating lymphocytes (TILs) and tertiary lymphoid structures (TLS) in localized oral tongue squamous cell carcinoma (OTSCC) remains unclear. This study investigates the prognostic impact of TILs and TLS on recurrence in patients with surgically treated OTSCC in NSND.
Methods
A total of 100 patients with OTSCC underwent complete surgical resection at a single institution with a median follow-up of 35 months (IQR 12-60). TIL presence (minimal, moderate, heavy) and TLS maturation (aggregate, primary follicle, secondary follicle) were graded using brightfield H&E slides according to previously published criteria. The prognostic impact of TILs and TLS on survival was analyzed using multivariable Cox regression, adjusting for prognostic factors (tumor size, depth of invasion, grade, and surgical margin status). Multivariable logistic regression was used to evaluate these factors for associations with early recurrence (≤12 months).
Results
Heavy TIL presence was observed in 41% of cases, and TLS was present in 76%, of which 23% were mature. The presence of mature TLS was associated with reduced odds of early recurrence [OR 0.18, P=0.04], and the presence of heavy TILs was associated with improved overall survival (OS) [HR 0.26, P=0.02]. Tumors categorized as TIL-/TLS- were associated with significantly worse OS [HR 3.5, P=0.02] compared to tumors with heavy TILs or mature TLS.
Conclusions
TILs and mature TLS are independently associated with decreased rate of early recurrence for high-risk localized OTSCC. Further studies should validate these potential low-cost biomarkers.
Editorial acknowledgement
During the preparation of this work the author(s) used Chat GPT in order to checking grammar. After using this tool/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract
184P - Alterations in tumorigenicity and immunogenicity of bladder cancer cells after somatic cell reprogramming
Presenter: Banu Iskender Izgi
Session: Poster Display session
Resources:
Abstract